Floatz logo

Everolimus

Renal Angiomyolipoma

Novartis PharmaceuticalsSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Renal Angiomyolipoma cohort.

Asset / SponsorPhaseRating
PROPRANOLOL
University Hospital, Bordeaux
Phase 2CCC
Ivocizumab
Fudan University
Phase 2CCC
Rapamycin
Dana-Farber Cancer Institute
Phase 2NR

Same molecule, other indications

Everolimus is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →